688137 Stock Overview
Researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Novoprotein Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.62 |
| 52 Week High | CN¥57.51 |
| 52 Week Low | CN¥28.56 |
| Beta | 2.07 |
| 11 Month Change | -3.35% |
| 3 Month Change | 18.85% |
| 1 Year Change | -36.05% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688137 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.5% | -2.6% | -2.1% |
| 1Y | -36.1% | -20.9% | 2.8% |
Return vs Industry: 688137 underperformed the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 688137 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 688137 volatility | |
|---|---|
| 688137 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688137 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688137's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 529 | Huaxing Zhu | www.novoprotein.com.cn |
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, and molecular enzymes and reagents; and gene and cell therapy, molecular research and diagnosis, and SRAS-CoV-2 and SARS-CoV-2 related products, as well as related technical services. The company also provides protein expression and purification, antibody, industrial strain and process development, stable cell line, VLP protein, protein crystallization, protein modification and labeling, MHC I-peptide complex protein preparation, antibody development, mRNA synthesis custom, and vaccine development services.
Novoprotein Scientific Inc. Fundamentals Summary
| 688137 fundamental statistics | |
|---|---|
| Market cap | CN¥2.41b |
| Earnings (TTM) | -CN¥21.29m |
| Revenue (TTM) | CN¥134.56m |
18.0x
P/S Ratio-113.5x
P/E RatioIs 688137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688137 income statement (TTM) | |
|---|---|
| Revenue | CN¥134.56m |
| Cost of Revenue | CN¥83.88m |
| Gross Profit | CN¥50.69m |
| Other Expenses | CN¥71.98m |
| Earnings | -CN¥21.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 37.67% |
| Net Profit Margin | -15.82% |
| Debt/Equity Ratio | 0% |
How did 688137 perform over the long term?
See historical performance and comparison